Sir, Hepatitis C virus (HCV) is an enveloped, positive-strand RNA virus and a major causative agent of acute and chronic hepatitis worldwide. Due to error-prone replication, HCV is highly variable and, based on phylogenetic analysis, viral isolates can be grouped into seven major genotypes. In addition, genetic recombination also increases RNA virus diversity and thereby constitutes an escape strategy from the host immune response as well as antiviral treatments. For HCV, naturally occurring recombinants are rare in vivo, but probably also underestimated due to genotyping of single genomic regions in HCV diagnostics. However, several epidemiologically important hybrid strains with different breakpoints have been described 1 including the homologous recombinant of genotype 2k/1b initially discovered in St Petersburg. 2 The 2k/1b chimeric virus is found at higher prevalence in countries belonging to the former Soviet Union. 3 This variant can be missed by most routine genotyping and can only be detected by specific targets or extended (a) sequencing of the HCV genome. 4 It has been shown in humanized mice infected with the 2k/1b variant that viral RNA levels drop in response to pegylated IFN-a (peg-IFN-a) treatment. 5 However, new regimens with direct-acting antivirals (DAAs) targeting the HCV non-structural proteins are not all pan-genotypic and data in patients infected with recombinant viruses are limited.
Here, we report a case of a male patient with a history of intravenous drug abuse. Before receiving his first antiviral treatment he had a fibroscan of 26.1 kPa suggesting liver cirrhosis although there had been no events of cirrhotic decompensation. According to Versant HCV Genotype 2.0 (LiPA), he had genotype 2a/2c. His first antiviral treatment with peg-IFN-a2b and ribavirin was terminated prematurely after 3 months due to insufficient virological response (Figure 1a) . After approval of DAA-based therapy, the patient received standard treatment for genotype 2 with sofosbuvir and ribavirin for 3 months according to current guidelines. 6 Although HCV-RNA became negative at week 4 of treatment the patient experienced viral relapse at follow-up week 4. Viral suppression was associated with a marked decrease in liver enzymes, whereas viral relapse was followed by an increase in liver enzymes (Figure 1a ). Standard sequencing of the NS5B polymerase region for detection of potential sofosbuvir resistance mutation revealed a genotype 1b-specific coding sequence indicative of an HCV chimeric strain. By applying total RNA next-generation sequencing, we identified the presence of an HCV 2k/1b variant at the timepoint before initial therapy and after sofosbuvir plus ribavirin treatment, confirming the initial misgenotyping (Figure 1a and b) As depicted in Figure 1(b) , the 5 0 -untranslated region (UTR) to NS2 regions of both analysed viral genomes (day 101 and day 630) showed the highest nucleotide sequence similarity to HCV subtype 2k, whereas NS2 to the 3 0 -UTR was most similar to subtype 1b. The breakpoint between genotypes 2k and 1b was pinpointed to a region in the NS2 gene between nucleotides 3175 and 3176, as previously observed in the reference 2k/1b genome sequence (GenBank accession number AY587845). Phylogenetic analysis revealed that both recombinant viral sequences cluster together with other 2k/1b chimera archived in the NCBI database in a distinct clade between genotype 1 and genotype 2 ( Figure 1c) . As the DAA target regions NS3/4A, NS5A and NS5B all lie within the genotype 1b section of the 2k/1b chimera, a treatment regimen suitable for genotype 1b rather than genotype 2 was supposed to be a sufficient antiviral treatment. Consequently, the patient was retreated with the genotype 1-specific so-called '3D' combination containing the NS3/4A PI paritaprevir (ABT-450), boosted by ritonavir, the NS5A inhibitor ombitasvir and the non-nucleotide NS5B polymerase inhibitor dasabuvir. The patient became HCV-RNA negative at week 4 of treatment and achieved a sustained virological response (SVR) at follow-up week 12 (Figure 1a) .
Due to limited information on the prevalence and response of the HCV 2k/1b recombinant to novel DAA treatment, no clear recommendations on therapy regimen and duration exist. Recently, lower SVR rates of sofosbuvir plus ribavirin treatment among patients infected with the 2k/1b chimera were reported, 7 which is in line with the relapse observed in the patient here. The standard treatment for genotype 2 (i.e. sofosbuvir plus ribavirin given for 3 months) showed only 10% SVR in genotype 1 patients who failed previous peg-IFN-a-based therapy. 8 The detection of these cases demonstrates the importance of determining the HCV genotype in the event of unsuccessful antiviral therapy in genotype 2. This can be achieved by NS5B sequencing, next-generation sequencing of the full genome or via RT-PCR methods, detecting parts of the 5 0 -UTR and NS5B domain, as employed in commercially available genotyping kits. It also highlights that genotype 1 therapies without genotype 2 approval are sufficient for the 2k/1b chimeric strains. However, it would be useful to have pan-genotypic therapies, which will not depend on the HCV genotype, subtype or intergenotypic recombinants. The recently approved combination sofosbuvir plus velpatasvir closes this gap. 9 However, costs and access have to be considered if a 'one pill fits all' regimen or individualized approaches based on genotype and other factors are used. 10 To our knowledge this is the first report of a successful antiviral therapy with the '3D' combination regimen against a 2k/1b chimera after failure of treatment with sofosbuvir and ribavirin.
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